Investigative study employs synchronous PET/MR imaging for tumor visualization, suggesting advances in nanomedicine applications.
Magnetic resonance imaging (MRI) and nuclear medicine imaging are widely used for cancer detection due to their high soft tissue resolution and sensitivity. Each modality has inherent limitations; therefore, integrated techniques such as positron emission tomography/magnetic resonance (PET/MR) have been developed. However, achieving simultaneous signal enhancement for both PET and MRI in clinical settings remains challenging. In this study, we employed gallium-68 ( 68 Ga)-labelled NaGdF 4 @RGD nanoprobes as a model system to establish a synchronous PET/MR imaging strategy for tumor diagnosis. These nanoprobes exhibited suitable radiochemical half-life, and effective tumor-associated targeting, enabling successful PET/MR imaging across multiple tumor models, including hepatoma, renal cancer, and breast cancer in vivo . Notably, this imaging strategy allowed time-resolved visualization of nanoprobe distribution and prolonged retention behavior in orthotopic liver tumors during delayed imaging periods, providing imaging-based insights into nanomedicine pharmacodynamics.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: